259
Views
2
CrossRef citations to date
0
Altmetric
Reviews

Beclomethasone dipropionate hydrofluoroalkane for the treatment of allergic rhinitis

, , , , &
Pages 279-288 | Received 31 Jul 2015, Accepted 06 Nov 2015, Published online: 11 Dec 2015
 

ABSTRACT

Allergic rhinitis (AR) is a common respiratory disease, and its prevalence is increasing all over the world, both in adults and in children. Patients experience symptoms that may negatively impact on physical, social and psychological well-being. Hence, if left untreated, allergic rhinitis may significantly affect quality of life. Under current guidelines, intranasal corticosteroids are considered the most effective drugs and they are recommended as first-line therapy. Among the several corticosteroid intranasal sprays available, beclomethasone dipropionate is one of the most prescribed. Recently, new intranasal hydrofluoroalkane-propelled formulations with little or no impact on the ozone layer have been developed for the treatment of AR. The use of these devices might improve patients’ adherence to treatment, avoiding some of the most common side effects associated with aqueous formulations. This review provides the most recent evidence for the efficacy and safety of beclomethasone dipropionate hydrofluoroalkane nasal aerosol in the treatment of allergic rhinitis.

View correction statement:
Erratum

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Key issues

  • Allergic rhinitis is an inflammation disease of the nose that may significantly affect quality of life and which worldwide prevalence is continuing to increase.

  • Under current guidelines, intranasal steroids are considered the most effective first-line therapy in treating allergic rhinitis.

  • Beclomethasone dipropionate (BDP) is one of the most prescribed glucocorticoids, being utilized for treatment of allergic rhinitis for decades with good efficacy and safety.

  • In 2012, BDP hydrofluoroalkane intranasal aerosol spray was introduced for the treatment of allergic rhinitis in subjects aged >12 years.

  • BDP hydrofluoroalkane intranasal aerosol is effective in treating symptoms of allergic rhinitis in both seasonal and perennial forms. To date, available results are encouraging, both in the short and long terms, in adults and in the pediatric population.

  • Intranasal BDP hydrofluoroalkane represents a specific new topic formulation that may provide additional options for clinicians to better individualize therapy based on patients’ preferences.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 718.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.